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PCV26
RATES OF VENOUS THROMBOEMBOLISM AND
ASSOCIATED INPATIENT HEALTHCARE
RESOURCE USE AMONG PATIENTS
UNDERGOING MAJOR ORTHOPEDIC SURGERY
IN AN INTEGRATED DELIVERY SYSTEM 
Boulanger L1, Hauch O2,Wygant G2, Dixon D1, Friedman M3,
Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA;
2AstraZeneca, L.P, Wilmington, DE, USA
OBJECTIVE: The objective of this study was to estimate
rates of venous thromboembolism (VTE) and inpatient
healthcare utilization following total hip replacement
(THR) or total knee replacement (TKR) surgery.
METHODS: Using a retrospective cohort approach and
inpatient data from a large Midwestern integrated health-
care organization, we evaluated all patients who under-
went a THR or TKR procedure between January 1, 1998
and September 30, 2000 and who received warfarin or
low-molecular-weight heparin (LMWH) prophylaxis
against deep vein thrombosis (DVT) during the initial
hospitalization. VTE rates (based on ICD-9-CM diag-
noses for pulmonary embolism or DVT) during the index
stay were estimated along with the associated incremen-
tal length of stay (LOS) and total charges. Time to VTE
occurrence within 90 days following index hospitaliza-
tion also was evaluated along with the associated LOS.
RESULTS: We identiﬁed 1411 patients who underwent
THR (N = 605) or TKR surgery (N = 806). For both pro-
cedures, warfarin was used 57% of the time versus 36%
for LMWH, while 7% of patients received both. The
mean LOS (±SD) for the initial hospitalization was 4.4 ±
2.0 days and mean charges were $22,150 ± $12,250. The
rate of VTE during the initial hospitalization was 1.1%
(15/1411) leading to an extra 3.7 ± 0.5 days (p < 0.01)
in hospital and $11,269 ± $3,168 in additional charges.
Following discharge, another 14 patients (1%) were read-
mitted for treatment of VTE with a mean LOS of 6.1 ±
7.8 days. Most of the readmissions for VTE (10 of 14)
occurred within 30 days. CONCLUSIONS: We found
that approximately 2% of patients receiving DVT pro-
phylaxis in this high-risk population were diagnosed with
thromboembolic events, which resulted in a signiﬁcant
health care burden and cost extending at least 90 days
beyond surgery. Whether this failure rate represents 
inadequate anti-coagulation or other risk factors requires
further study.
PCV27
THE IMPACT OF ATHEROTHROMBOTIC
EVENTS ON RESOURCE USE AND COST IN
PATIENTS WITH PERIPHERAL ARTERIAL
DISEASE
Caro J1, Migliaccio-Walle K1, Ishak K2, O’Brien JA1
1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada
OBJECTIVES: To estimate the resource use and costs
associated with atherothrombotic events following 
the diagnosis of peripheral arterial disease (PAD).
METHODS: We evaluated resource use and costs 
following a recorded diagnosis (identiﬁed using ICD-9
codes) of PAD using the healthcare records of residents
of Saskatchewan, Canada who were diagnosed between
1985–1995. Data on patient characteristics and medical
history were available from January 1980 and follow-up
was complete to December 2000. Rates of resource use
(hospitalizations, visits, procedures) were determined by
dividing the cumulative amount of use by the patient time
in a given period. Unit costs (2002 Canadian dollars)
were applied to the corresponding resource use to obtain
the mean costs. In this paper, the impact of athero-
thrombotic (myocardial infarction, angina, stroke, TIA)
hospitalizations is considered and compared to that in
patients with myocardial infarction and stroke.
RESULTS: Among 16,440 patients with PAD, 54.9%
were male, mean age was 67.3 years, 58% died during
follow-up, 85.8% were hospitalized at least once and one
third (37.1%) had at least one atherothrombotic-related
hospitalization, a hazard of 6.5/100 person-years. Among
those hospitalized, there were 2.1 atherothrombotic hos-
pitalizations on average. The hazard was highest imme-
diately following diagnosis (30.5/100PY) but dropped
rapidly to 25.3 in the second month, 16.8 by month 6
and 13.7 by the end of the ﬁrst year. This translated to a
monthly cost of $80.40 per patient in the ﬁrst month
(66.3% of total hospitalization cost), dropping to $45.70
at year end (77.1% of total). These atherothrombotic
event costs amounted to $28.3 million in years 2–5;
whereas, patients suffering a myocardial infarction or
stroke incurred $28.2 million and $31.0 million, respec-
tively. CONCLUSIONS: Hospitalizations for atherothro-
mbotic events account for a substantial portion of the
costs of managing patients with PAD.
PCV28
ECONOMIC OUTCOMES ASSOCIATED WITH
CHOICE OF TREATMENT IN DEEP VENOUS
THROMBOSIS AND PULMONARY EMBOLISM
Knight KK1,Wong JY1, Hauch O2,Aguilar D1, Reynolds M2,
Wygant G2, Ofman JJ1
1Zynx Health Incorporated, Beverly Hills, CA, USA;
2AstraZeneca, LP, Wilmington, DE, USA
OBJECTIVES: To describe costs and utilization associ-
ated with common inpatient treatments for deep venous
thrombosis (DVT) and pulmonary embolism (PE).
METHODS: Data from medical records were collected
for DVT and PE admissions (identiﬁed using Diagnostic
Related Group [DRG] or All Patient Reﬁned DRG codes)
from 132 hospitals between January 1999 and December
2000. Admissions were classiﬁed by treatment, including
unfractionated heparin (UFH) and low-molecular-weight
heparin (LMWH) monotherapies, UFH with LMWH,
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UFH with vitamin K antagonist (VKA, e.g. warfarin),
LMWH with VKA, and UFH with LMWH and VKA.
Admissions using the three most common treatments
were compared with respect to length of stay (LOS), med-
ication costs and hospitalization costs. RESULTS: A total
of 953 primary DVT and 3933 primary PE admissions
were identiﬁed. Demographics were comparable for DVT
and PE patients. Most encounters involved treatment
with UFH/VKA (64%), followed by UFH/LMWH/VKA
(14%), and LMWH/VKA (13%). Median (interquartile
range) LOS for DVT patients treated with UFH/VKA,
UFH/LMWH/VKA, and LMWH/VKA were 5 (4–7), 5
(3–7), and 4 (2–6) days, respectively (p < 0.0001); corre-
sponding ﬁgures for PE patients were 6 (5–8), 6 (4–8),
and 5 (3–7) days, respectively (p < 0.0001). Median
(interquartile range) total hospitalization costs for 
DVT admissions were $3059 ($2251–$4306), $3515
($2106–$5351), $2587 ($1776–$3827) respectively (p <
0.0002). Corresponding costs for PE admissions were
$5152 ($3888–$7015), $5668 ($4077–$7928), $4537
($3144–$6168), respectively (p < 0.0001). UFH/LMWH/
VKA treatment was associated with the highest total drug
cost, while UFH/VKA treatment was associated with
lower anticoagulant and total medication costs. Higher
medication costs in the LMWH/VKA group were more
than offset by lower costs in other areas (shorter LOS)
yielding lower overall hospitalization costs. CONCLU-
SIONS: UFH/VKA was the most commonly employed
treatment, and was associated with lower medication
costs as compared to LMWH/VKA. However, LMWH/
VKA treatment was associated with reduced LOS and
lower overall hospitalization costs.
PCV29
HEALTH SERVICE UTILIZATION, COSTS AND
OUTCOMES OF PATIENTS WHO USED
DIFFERENT TYPES OF CALCIUM CHANNEL
BLOCKERS FOR HYPERTENSION
Liu X,Yu W
WellPoint Pharmacy Management, West Hills, CA, USA
OBJECTIVES: To compare health service utilization,
costs and outcomes of patients who used dihydropyridine
(DHP) and non-DHP calcium channel blockers (CCB) for
hypertension. METHODS: Utilizing pharmacy, member-
ship and medical data from a large managed care health
plan of over 2 million commercial members, this study
included continuously enrolled patients who had at least
2 or more CCB claims (DHP or non-DHP) between Juny
2000 and June 2001 and did not have a CCB claim 6
months prior to the index claim. Patients were followed
for 12 months after the index prescription and those who
had drug coverage for at least 60% of the days during
the follow-up period were included in the study. Geocod-
ing using national census data was performed to extract
socioeconomic data. Propensity-score matching of DHP
and non-DHP group was performed to adjust for selec-
tion bias. Overall and hypertension-related pharmacy and
medical service utilization and costs, and prevalence of
new renal and vascular-related diagnoses during follow-
up were determined for each study group. RESULTS: A
total of 4443 pairs of propensity-score matched patients
were included in the DHP and non-DHP study group.
Prevalence of new diagnosis for ischemic cerebrovascular
disease was lower in the non-DHP group than in the DHP
group (1.8% vs 2.5%; p < 0.05). Statistically signiﬁcant
difference in prevalence of new diagnosis for renal insuf-
ﬁciency, kidney dialysis, or proteinuria was not observed.
Average hypertension-related pharmacy and medical
costs were signiﬁcantly lower in the non-DHP group
($168 and $260) than in the DHP group ($184 and $370;
p < 0.05). The inter-group difference in costs was larger
among patients who used angiotensin converting enzyme
inhibitors (ACEI) concurrently with CCB. CONCLU-
SION: Treatment of hypertension with non-DHP CCB is
associated with lower prevalence of ischemic cerebrovas-
cular disease and lower pharmacy and medical costs as
compared to DHP CCBs, especially when used concur-
rently with ACEI.
PCV30
ECONOMIC EVALUATION OF LOSARTAN
COMPARED WITH ATENOLOL IN THE
TREATMENT OF HYPERTENSION WITH LEFT
VENTRICULAR HYPERTROPHY: A COST-
MINIMIZATION ANALYISIS BASED ON LIFE
STUDY
Chevreul K1, Durand-Zaleski I2, Souchet T3
1Robert Debré Hospital, Paris, France; 2Hôpital Henri Mondor,
Paris, France; 3Merck Sharp & Dohme—Chibret, Paris, France
OBJECTIVE: The LIFE Study demonstrated a signiﬁcant
reduction in cardiovascular morbidity and mortality in
hypertensive patients with ECG left ventricular hyper-
trophy treated with losartan (versus treatment with
atenolol) over a mean period of 4.8 years. This reduction
was essentially related to a signiﬁcant 25% decrease (p =
0.001) in the risk of fatal and non-fatal stroke. The objec-
tive of this study was to compare the treatment costs
relating to each therapeutic strategy throughout the dura-
tion of the LIFE Study. METHODS: Data on efﬁcacy and
resources consumed were extracted from the published
results of the LIFE study. A cost minimization study was
carried out and the costs were calculated from the point
of view of the French healthcare system. The total esti-
mated direct costs included those relating to the medici-
nal product and management of the cardiovascular events
(myocardial infarction, angina pectoris, heart failure,
stroke and revascularization). The medicinal products
were valued on the basis of the purchasing price (retail
price inc. VAT), and hospitalization costs were estimated
on the basis of PMSI data and the national cost scale.
Indirect costs were not considered. RESULTS: Over the
4.8 years, the mean cost of losartan per patient ranged
